Evidence map›Paper›PMID 35166466›Full record

ArticleNeuropsychopharmacology reports2022

A case report: Clozapine-induced leukopenia and neutropenia after mRNA COVID-19 vaccination.

Tomoyuki Imai, Sho Ochiai, Takehiro Ishimaru, Hayato Daitoku, Yusuke Miyagawa, Ryuji Fukuhara, Shuken Boku, Minoru Takebayashi

Open access · goldAbstract readCase Reports
In one paragraph

Article in Neuropsychopharmacology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Tomoyuki ImaiDepartment of Neuropsychiatry, Kumamoto University Hospital, Kumamoto, Japan.ORCID 0000-0001-6858-1145
Sho OchiaiDepartment of Neuropsychiatry, Kumamoto University Hospital, Kumamoto, Japan.
Takehiro IshimaruComprehensive Clinical Education, Training and Development Center, Kumamoto University, Kumamoto, Japan.
Hayato DaitokuMinamata City General Hospital and Medical Center, Minamata, Japan.
Yusuke MiyagawaDepartment of Neuropsychiatry, Kumamoto University Hospital, Kumamoto, Japan.
Ryuji FukuharaDepartment of Neuropsychiatry, Kumamoto University Hospital, Kumamoto, Japan.
Shuken BokuDepartment of Neuropsychiatry, Faculty of Life Science, Kumamoto University, Kumamoto, Japan.
Minoru TakebayashiDepartment of Neuropsychiatry, Kumamoto University Hospital, Kumamoto, Japan.ORCID 0000-0001-9962-8444
Kumamoto University Hospital · JPKumamoto Health Science University · JPGeneral Hospital of Drama · GRKumamoto Educational Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia and is known to cause serious side effects, such as leukopenia and neutropenia. We encountered the case of a 44-year-old female patient with a good response to clozapine, who experienced inflammatory reaction and cytopenia after coronavirus disease 2019 (COVID-19) vaccination. Soon after clozapine discontinuation, the inflammatory reaction resolved, and cell counts recovered. There are only a few reports on the interaction between clozapine and COVID-19 vaccine. Our findings suggest that caution is required when a patient who is receiving clozapine scheduled for COVID-19 vaccination, owing to the possibility of cytopenia. Moreover, blood tests and the measurement of clozapine concentration should be performed before and after the inoculation to ensure patient safety.

Indexed as

ClozapineCOVID-19COVID-19 Drug TreatmentNeutropeniaSchizophreniaAdultCOVID-19 VaccinesFemaleHumansRNA, MessengerVaccinationClozapineCOVID-19 VaccinesRNA, MessengerclozapineCOVID-19 vaccineleukopenianeutropeniaschizophrenia

Identifiers

PMID35166466
PMCPMC9216366
OpenAlexW4213166037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.